$派格生物医药-B(_老虎社区_美港股上老虎

$派格生物医药-B(02565)$ 中国作为潜在的全球最大肥胖和糖尿病患者市场，监管环境正逐步松动，临床试验和本土创新亦全面提速

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":506958661751048,"tweetId":"506958661751048","gmtCreate":1764745592911,"gmtModify":1764747004292,"author":{"id":4108169486081000,"idStr":"4108169486081000","authorId":4108169486081000,"authorIdStr":"4108169486081000","name":"抄底大将军","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":41,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","html":"<html><head></head><body><p><a href=\"https://laohu8.com/S/02565\">$派格生物医药-B(02565)$ </a> 中国作为潜在的全球最大肥胖和糖尿病患者市场，监管环境正逐步松动，临床试验和本土创新亦全面提速</p></body></html>","htmlText":"<html><head></head><body><p><a href=\"https://laohu8.com/S/02565\">$派格生物医药-B(02565)$ </a> 中国作为潜在的全球最大肥胖和糖尿病患者市场，监管环境正逐步松动，临床试验和本土创新亦全面提速</p></body></html>","text":"$派格生物医药-B(02565)$ 中国作为潜在的全球最大肥胖和糖尿病患者市场，监管环境正逐步松动，临床试验和本土创新亦全面提速","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/506958661751048","repostId":0,"isVote":1,"tweetType":1,"viewCount":351,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["02565"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":113,"optionInvolvedFlag":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}